Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ChromaDex Corporation
< Previous
1
2
3
Next >
ChromaDex to Report Third Quarter Financial Results on Wednesday, November 2, 2022
October 26, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex’s Tru Niagen® Won the "Most Popular Brand of the Year Award" at China International Natural Health & Nutrition Expo’s (NHNE) Prestigious Nutrition Planet Awards
October 24, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment
October 11, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
Sinopharm Xingsha to Introduce ChromaDex’s Tru Niagen® at Major Mainland China Trade Show, China International Natural Health & Nutrition Expo (NHNE)
September 19, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Shares Promising Findings from Clinical Study Showcasing the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction
October 04, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex’s Intellectual Property Held Under Exclusive License From Dartmouth College
August 15, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Finalizes Commercial Joint-Venture in Asia and Announces $3.1 Million Private Placement of Common Stock
October 03, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Corporation Reports Second Quarter 2022 Financial Results
August 10, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
August 02, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen® and Tru Niagen® PRO into Brazil
September 01, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex To Host Key Opinion Leader Webinar on the Transforming Benefits of Nicotinamide Riboside (NR)
July 07, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and Federation of American Societies for Experimental Biology (FASEB)
June 15, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Present at the Oppenheimer’s 22nd Annual Consumer Growth and E-Commerce Conference
June 07, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Partners with Juvenis for Cross-Border Sales of Tru Niagen® into South Korea
June 02, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen® into Mainland China
June 10, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Present at the LD Micro Invitational
June 01, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland China
May 19, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Wins International 2022 European NutraIngredients Award for Developing the Science Behind Niagen®
May 17, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Corporation Reports First Quarter 2022 Financial Results
May 12, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
April 29, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Appoints Ann Cohen and Kristin Patrick to its Board of Directors
April 22, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex External Research Program (CERP™) Celebrates Over 250 Research Agreements With 235+ Researchers Around the World
April 14, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Launches Tru Niagen® Immune, Further Expanding Innovative Product Portfolio
April 06, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Announces Issuance of Additional New U.S. Continuation Patent, Further Protecting Future Innovations
March 16, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Report Fourth Quarter 2021 Financial Results on Wednesday, March 9, 2022
February 22, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Announces Issuance of New U.S. Continuation Patent, Expanding Intellectual Property Portfolio for Nicotinamide Riboside
February 09, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex External Research Program (CERP™) Celebrates 100 Peer-Reviewed Published Studies on Niagen® and Other Ingredients
January 31, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (NR) Supplementation
January 25, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex and Designs for Health Partner for New Product Development on Niagen®
January 20, 2022
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Corporation Reports Third Quarter 2021 Financial Results
November 03, 2021
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.